/** blogpostTitle: Anupam Rasayan FY26: Scale-up Year, Margin Dip, and a Platform Strategy blogpostSlug: anupam-fy26 blogpostCoverImageDescription: Ultra-realistic corporate financial cover image showing a clean desk setup with a laptop displaying a dashboard of line charts and bar charts. The charts depict strong year-on-year revenue growth and operating cash flow improvement, alongside a separate chart showing quarterly EBITDA margin compression. Include subtle visual cues of global expansion such as a world map with highlighted nodes for India and the United States, and a small schematic of three connected blocks representing backward integration, core intermediates, and U.S. custom synthesis. No logos and no readable text. blogpostShortTitle: Anupam Rasayan FY26 growth and acquisitions */

Anupam Rasayan FY26: Scale-up Year, Margin Dip, and a Platform Strategy

Anupam Rasayan India Limited closed FY26 with its highest reported annual performance, helped by scale-up in its specialty chemicals business and a larger consolidated footprint. Consolidated total income for FY26 rose to INR 2,383.63 crore, up 65% year on year from INR 1,448.45 crore. EBITDA increased 32% to INR 543.00 crore, while profit after tax grew 39% to INR 222.20 crore.

The quarter, however, told a more nuanced story. In Q4FY26, consolidated total income grew 26% year on year to INR 639.15 crore, but EBITDA declined 6% to INR 140.70 crore and the margin fell to 22% from 30% in Q4FY25. PAT also declined 11% to INR 56.00 crore. The financials reflect the reality of a company expanding through acquisitions and product mix shifts, where the full benefits of scale and synergies do not always appear smoothly each quarter.

A key context item for FY26 is consolidation timing. Management stated that FY26 includes Tanfac and only 1 month and 2 days of Jayhawk Fine Chemicals. The company also highlighted that Jayhawk began contributing to revenue from 27 February 2026. That detail matters because FY27 will be the first year in which the U.S. acquisition is visible across a full operating period.

FY26 in numbers: strong growth, mixed quarterly profitability

On a consolidated basis, FY26 improved sharply on scale. Revenue from operations increased to INR 2,365.46 crore from INR 1,436.97 crore in FY25. The company also reported improved cash generation. Net cash from operating activities stood at INR 334.33 crore in FY26 versus negative INR 30.13 crore in FY25.

Balance sheet expansion was significant. Total consolidated assets rose to INR 8,012.60 crore as of March 2026 from INR 5,268.88 crore in March 2025. A large part of this came from the U.S. acquisition-related consolidation. The consolidated balance sheet shows goodwill of INR 663.46 crore as of March 2026 compared to INR 123.21 crore in March 2025.

At the same time, the quarter showed margin pressure. EBITDA margin for Q4FY26 was 22% versus 30% in Q4FY25. This is the kind of outcome investors will keep tracking because the company is positioning itself as a higher value, complex chemistry and CDMO platform where stability of margins and working capital discipline are central to long-term compounding.

Note: Figures are taken from the investor presentation and audited consolidated statements (amounts converted to INR crore).

Portfolio shift: reducing agro dependence, building higher value verticals

The investor presentation positions Anupam Rasayan as a custom synthesis manufacturer with business verticals spanning life sciences and performance materials. On a standalone basis for FY26, the company disclosed a revenue mix of 55% from agrochemicals, 20% from performance materials, 18% from personal care, and 7% from pharma.

Management also discussed how the mix has evolved over time. In the earnings call, the Managing Director stated that dependence on agrochemicals reduced from 76% of revenue contribution in FY22 to 55% in FY26. Management also highlighted that on a standalone basis high-performance materials revenue increased from INR 97 crore in FY22 to INR 305 crore in FY26, while pharma revenue grew from INR 21 crore in FY22 to INR 339 crore in FY26.

The shift is not presented as a move away from agro, but as a deliberate diversification into segments with different demand cycles and higher entry barriers. The company emphasizes complex chemistries where customer qualification cycles are long and switching costs are high.

Note: Disclosed as standalone revenue mix in the investor presentation.

The platform thesis: Tanfac, Jayhawk, and the proposed Bliss deal

FY26 is also important because the strategic narrative is now anchored on a multi-entity platform.

First, Tanfac is described as the backward integration pillar for fluorination chemistry. The presentation notes that Anupam acquired about 26% stake in Tanfac in May 2022 for about INR 153 crore. It positions Tanfac as a producer of key raw materials HF and KF, enabling uninterrupted access and reducing import dependence. Tanfac revenue is shown rising to INR 711 crore in FY26.

Second, the Jayhawk acquisition is the flagship global move. The investor deck states that Jayhawk Fine Chemicals, founded in 1941 and headquartered in Kansas, U.S., manufactures performance materials (about 65%) and life or crop science molecules (about 35%). Anupam acquired Jayhawk at an enterprise value of about $134 million, with total purchase consideration of about$150 million including cash on Jayhawk’s balance sheet. Jayhawk’s 2026 key financials are described as about $76 million revenue and about$15 million EBITDA (about 19% margin). Management stated that only a short period was consolidated in FY26, implying FY27 will reflect a more complete picture.

Third, the forward integration step is the signed definitive agreement to acquire Bliss GVS Pharma. The company’s regulatory filing discloses an SPA for 43.30% equity stake at INR 299 per share (aggregate up to INR 1,369.51 crore) and an open offer for up to 26% at INR 299 per share (aggregate up to INR 829.03 crore). The disclosures state the acquisition is intended to strengthen presence across the pharmaceutical value chain from KSMs to finished dosage formulations.

In the earnings call, management added more color. They stated Bliss management would continue, similar to the approach taken with Tanfac and Jayhawk. They also stated Bliss operates at about 30% utilisation and they see scope to enhance it to 60% to 70% over near to medium term. On funding, management indicated around INR 300 crore of debt through NCDs, along with other funding elements through an acquisition vehicle.

Capital allocation, capex stance, and what to track

A notable management statement from the call was the near-term capex posture for the standalone business. Management stated it did capex of around INR 315 crore during FY26 toward the last leg of the capex program and that all plants are commercialized. They also stated they are not envisaging any major capex in the near future, with maintenance capex indicated at around INR 50 crore to INR 75 crore.

On growth visibility, the investor presentation lists signed LOIs and contracts totaling INR 14,646 crore across multiple customers, segments and tenors. Some items are marked as commercialization started, while others are expected to commercialize in FY27 or FY28. In the earnings call, management linked this pipeline to growth aspirations and also stated it would strive for around 20% to 25% or 30% CAGR over the next 3 to 5 years.

The other major item investors will monitor is leverage. In the call, management stated consolidated gross debt is around INR 1,500 crore and net debt around INR 1,100 crore, with more than two-third being working capital loans. In FY26, consolidated finance cost was INR 148.71 crore versus INR 112.22 crore in FY25.

The quarter-level margin compression combined with a higher finance cost base makes cash generation and working capital efficiency key. FY26 delivered a sharp turnaround in operating cash flow at INR 334.33 crore consolidated, and management also stated that working capital improved over the year.

Key takeaways

FY26 marks a step-up year for Anupam Rasayan, with the consolidated P and L reflecting scale and improved operating cash flow, while Q4 profitability shows the friction that can come with mix shifts and a growing platform.

The strategic direction is now clear. The company is attempting to build an integrated specialty chemicals and CDMO platform through backward integration in fluorination via Tanfac, a U.S. custom synthesis footprint via Jayhawk, and a proposed move into finished dosage formulations via Bliss GVS Pharma.

For investors, FY27 will likely be a more revealing year. It should include a full-year Jayhawk contribution and, if completed, the early phases of Bliss integration. The major questions will revolve around whether margins normalise from the Q4 dip, whether working capital stays on an improving path, and how quickly the platform strategy translates into measurable operating outcomes.